BioSpace News Archive

MannKind Corporation announced that its Chief Executive Officer, Michael Castagna, PharmD, will present at the 2023 Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023 at 11:15 AM PST at the Westin St. Francis Hotel in San Francisco, California.

KalVista Pharmaceuticals, Inc. announced the promotion of Ben Palleiko, the Company’s current Chief Business Officer and Chief Financial Officer, to the additional title of President.

Merck, known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2022 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. ET on Thursday, February 2.

Amryt is pleased to announce positive results from its APH-19 Phase 3 trial of lomitapide for the treatment of Homozygous Familial Hypercholesterolemia in children aged 5-17 years.

Orchard Therapeutics, a global gene therapy leader, announced the U.S. Food and Drug Administration has cleared its Investigational New Drug application for OTL-203, a hematopoietic stem cell gene therapy being developed for the treatment of the Hurler subtype of mucopolysaccharidosis type I.

Myriad Genetics, Inc. announced its support for a recent guideline update by the American College of Medical Genetics and Genomics, reaffirming the clinical value of non-invasive prenatal screening for a range of chromosomal abnormalities.

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, announced a comprehensive update on its future clinical development plans.

Nanoscope Therapeutics Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, announced the appointment of Massoud Motamed, Ph.D., as Vice President of Quality.

Zimmer Biomet Holdings, Inc. announced that it has reached a definitive agreement to acquire Embody, Inc., a privately-held medical device company focused on soft tissue healing, for $155 million at closing and up to an additional $120 million subject to achieving future regulatory and commercial milestones over a three year period.

Neogen Corporation announced the results of the second quarter ended November 30, 2022.